Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age

Philip L. McCarthy, Theresa Hahn, Anna Hassebroek, Christopher Bredeson, James Gajewski, Gregory Hale, Luis Isola, Hillard M. Lazarus, Stephanie J. Lee, Charles F. LeMaistre, Fausto Loberiza, Richard T. Maziarz, J. Douglas Rizzo, Steven Joffe, Susan Parsons, Navneet S. Majhail

Research output: Contribution to journalArticle

70 Scopus citations

Abstract

Autologous hematopoietic cell transplantation (auto-HCT) is performed to treat relapsed and recurrent malignant disorders and as part of initial therapy for selected malignancies. This study evaluated changes in use, techniques, and survival in a population-based cohort of 68,404 patients who underwent first auto-HCT in a US or Canadian center between 1994 and 2005 and were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The mean annual number of auto-HCTs performed was highest during 1996-1999 (6948), and decreased subsequently 2000-2003 (4783), owing mainly to fewer auto-HCTs done to treat breast cancer. However, the mean annual number of auto-HCTs increased from 5278 annually in 1994-1995 to 5459 annually in 2004-2005, reflecting increased use for multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Despite an increase in the median recipient age from 44 to 53years, there has been a significant improvement in overall survival (OS) from 1994 to 2005 in patients with chemotherapy-sensitive relapsed non-Hodgkin lymphoma (day+100 OS, from 85% to 96%; 1-year OS, from 68% to 80%; P<.001) and chemotherapy-sensitive multiple myeloma (day+100 OS, from 96% to 98%; 1-year OS, from 83% to 92%; P<.001). This improvement in OS was most pronounced in middle-aged (>40years) and older (>60years) individuals.

Original languageEnglish (US)
Pages (from-to)1116-1123
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number7
DOIs
StatePublished - Jul 1 2013

Keywords

  • Autologous transplantation
  • Lymphoma
  • Myeloma
  • Survival
  • Treatment-related mortality

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age'. Together they form a unique fingerprint.

  • Cite this

    McCarthy, P. L., Hahn, T., Hassebroek, A., Bredeson, C., Gajewski, J., Hale, G., Isola, L., Lazarus, H. M., Lee, S. J., LeMaistre, C. F., Loberiza, F., Maziarz, R. T., Rizzo, J. D., Joffe, S., Parsons, S., & Majhail, N. S. (2013). Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age. Biology of Blood and Marrow Transplantation, 19(7), 1116-1123. https://doi.org/10.1016/j.bbmt.2013.04.027